Seattle Genetics

21823 30th Drive SE
Bothell, WA 98021

USA

Phone: (425) 527-4000
Fax: (425) 527-4001
Email: contact@seagen.com
Web Site: http://www.seattlegenetics.com

A. Company Profile

Seattle Genetics (NASDAQ:SGEN) is a biotechnology company focused on developing monoclonal antibody-based therapeutics for cancer.

B. Products

Product Pipelines

1. SGN-33

SGN-33, lintuzumab, is a humanized monoclonal antibody that targets the CD33 antigen, which is highly expressed on a number of hematologic malignancies, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and several myeloproliferative disorders. CD33 is an attractive target for antibody-based therapy because of its limited expression on normal cells.

2.SGN-35

SGN-35 is an antibody-drug conjugate consisting of an anti-CD30 monoclonal antibody attached by a proprietary, enzyme-cleavable linker to a derivative of the highly potent class of cell-killing drugs called Auristatins. The ADC binds to receptors on target cells, undergoes rapid internalization and then releases active drug from the antibody carrier inside the cell. The linkage system is highly stable in plasma. Thus, SGN-35 is designed to have low toxicity and high specificity for antigen positive target cells.

3. SGN-40

SGN-40 is a humanized Mab targeted to the CD40 antigen, which is expressed on hematologic malignancies such as multiple myeloma and non-Hodgkin's lymphoma.